


EXPRESS MAIL CERTIFICATE



Date \_\_\_\_\_ Label No. \_\_\_\_\_

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to Mail Stop Non-Fee Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "Express Mail Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Name (Print)

Signature

Customer No.: **07278**

Docket No: **03394/100H557-US1**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Ehud Goldin et al.

Serial No.: 09/851,494

Art Unit: 1646

Confirmation No.:

Filed: May 8, 2001

Examiner: John D. Ulm

For: **A Gene Encoding A New TRP Channel Is Mutated In Mucolipodosis IV**

**DECLARATION UNDER 37 C.F.R. § 1.131**

Mail Stop Non-Fee Amendments  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

We, EHUD GOLDIN, SUSAN A. SLAUGENHAUPT, MEI SUN, and JAMES S. ACIERNO, JR. hereby declare and state as follows:

Serial No. 09/851,494

Docket No: 03394/100H557-US1

Page 1

**BEST AVAILABLE COPY**

1. Susan A. Slaugenhouette and James S. Acierno, Jr. are citizens of the United States of America. Ehud Goldin is a citizen of Israel. Mei Sun is a citizen of China. Each of us is more than twenty-one years of age.

2. We are the inventors of the above-identified application.

3. We reaffirm our duty of candor and good faith in dealing with the Office, including the duty to disclose to the Office all information known to be material to the patentability of the invention as defined in 37 C.F.R. § 1.56.

4. We have read and are familiar with the instant application as it was filed in the U.S. Patent and Trademark Office.

5. We have read and are familiar with the publications by (i) Curtis et al. (Pub. No. US 2002/0035056 A1), which we understand has an effective filing date under 35 U.S.C. 119(e) of Apr. 07, 2000; and (ii) Lal et al. (Pub. No. US 2002/0182671 A1), which we understand has an effective filing date under 35 U.S.C. 119(e) of Aug. 17, 1999.

6. It is our understanding that, according to the Examiner, the amino acid sequence presented in SEQ ID NO: 3 of the instant application is identical to the amino acid sequence presented in SEQ ID NO: 2 of Curtis et al. and SEQ ID NO: 13 of Lal et al. It is further our understanding that the Examiner states that Curtis et al. and Lal et al. each present an isolated nucleic acid encoding a protein comprising the amino acid sequence presented in SEQ ID NO: 3 of the instant application, as well as a vector and host cell comprising that nucleic acid.

7. Prior to Aug. 17, 1999, the effective date of the Lal et al. publication, we conceived and reduced to practice the invention as described and claimed in claims 1, 5-7, 33-34, and 39 of the subject application.

8. The inventive work embodied in all claims of the subject application was carried out in its entirety in the United States of America.

9. As evidence that our reduction to practice antedates Lal et al., we refer to Exhibits 1 and 2, which collectively establish the conception and reduction to practice of our invention prior to Aug 17, 1999. The exhibits verify the isolation and possession of a nucleic acid encoding MCOLN1 prior to Aug. 17, 1999. Dates, along with privileged information, appearing in these documents have been redacted, but each document has a date before August 17, 1999.

10. Exhibit 1 establishes identification of MCOLN1 sequence, showing the receipt by Dr. Slaugenhaupt of two primers: (i) sts-T66288-R (5'-AGC TGC AGG CCT ACA TCG -3'); and (ii) sts-T66288-F (5'GGC AGT CAG GTC GAA TCA AT-3). As shown in Appendix A, the two primers are specific to the MCOLN1 gene, spanning the 1732-1883 bp region of the MCOLN1 cDNA sequence (SEQ ID NO: 3).

11. Exhibit 2 shows the identification and possession of a nucleic acid encoding a full-length MCOLN1 protein by presenting an EST alignment spanning the MCOLN1 gene. At least two notations are particularly relevant. First, this page shows a "2264 bp" annotation of T66288 following sequencing, indicating that T66288 encodes the entire MCOLN protein. Prior to our sequencing, the exact insert size of this construct was not known.

Second, this page also identifies the orientation of AI8166064, which is the corresponding GenBank accession number for IMAGE CLONE 2517653 (Appendix B). Paragraph [0185] of the specification states that we "sequenced the IMAGE clone 2517653." This paragraph further describes our deduction and confirmation of the MG-2 (MCOLN) open-reading frame from this clone.

12. With the isolation and identification of the MCOLN1 coding region, we also achieved reduction to practice of an expression vector encoding the MCOLN1 protein prior to August 17, 1999. Appendix B reveals that IMAGE CLONE 2517653 (as presented in Exhibit 2) is inserted into the pBlusescrit SK+ vector. This common vector is widely recognized by those skilled in the art of molecular biology as including T3 and T7 promoters that flank the cloning site, which allow expression of the inserted gene sequence. Appendix C shows the key structural features of this vector. The entire MCOLN1 open reading frame is present in IMAGE CLONE 2517653.

13. These documents verify our reduction to practice in the United States of America, prior to Aug. 17, 1999, of the subject matter of claims 1, 5-7, 33-35, and 39.

14. We further declare that all statements made herein of our own knowledge are true, and that all statements made on information and belief are believed to be true. We further declare that these statements are made with the knowledge that the willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United Stated Code, and that such willful false statements may jeopardize the validity of the instant application or of any patent issued thereupon.

Respectfully submitted,

11/28/2004

DATE



Ehud Goldin

DATE

Susan A. Slaugenhouette

DATE

Mei Sun

DATE

James S. Acierno, Jr

Respectfully submitted,

---

DATE

12-13-04

---

DATE

---

Ehud Goldin



Susan A. Slaugenhaft

---

DATE

---

Mei Sun

---

DATE

---

James S. Acierno, Jr

Respectfully submitted,

---

DATE

---

Ehud Goldin

---

DATE

---

Susan A. Slaugenhouette

---

DATE

---

Mei Sun

---

DATE

---

James S. Acierno, Jr

Respectfully submitted,

---

DATE

---

Ehud Goldin

---

DATE

---

Susan A. Slaugenhaupt

---

DATE

---


Mei Sun

---

12/19/04

---

DATE



James S. Acierno, Jr

## EXHIBIT A PAGE 1



## Oligonucleotide Specification Sheet

## Customer Information

Susan Slaugenhouette  
Harvard Institute of Human Genetics  
Massachusetts General Hospital-Boston  
77 Avenue Louis Pasteur HIM Bldg. Rm. 422  
Boston, MA 02115  
6174327025

1740 Commercial Park  
Corona del Mar, CA 92621  
Phone: 800-328-2861  
Fax: 714-828-8444  
E-Mail: orders@idtdna.com  
<http://www.idtdna.com>

## Order Information

Order Date : **19479**  
Customer # : **19479**  
P.O. # : **0000085288**

Sales order # : **148396**  
Reference # : **624757**

## Oligonucleotide Information

Reference # : **624757**  
Purification : **Standard Purification**  
Sequence Name : **sts-T66288-1**

Product : **DNA Oligo Sample**  
Unit Size : **100 nmole**  
Bases : **20**

Sequence : **5'- GGC AGT CAG GTC GAA TCA AT -3'**

$$\begin{array}{r} 10 \times 4 = 40 \\ 10 \times 2 = 20 \\ \hline 60 \end{array}$$

Molecular Weight :	<b>7,572.00</b>
GC Content :	<b>50.0 %</b>
Tm (50mM NaCl) :	<b>51.44 °C</b>

<b>Amount of Oligo</b>		
<b>21.8</b>	<b>= 95.01</b>	<b>= 0.72</b>
OD <sub>260</sub>	nanomoles	mg

Printed 6/9/99

1569

## LABELS - PEEL HERE

624757 Integrated DNA Tech  
S. Slaugenhouette 06/09/99  
sts-T66288-1  
5'-GGC AGT CAG GTC GAA TCA AT -3'  
Tm = 51.44 °C, MW = 7572  
21.80 OD<sub>260</sub> = 95.01 nmol = 0.72 mg

624757 Integrated DNA Tech  
S. Slaugenhouette 06/09/99  
sts-T66288-1  
5'-GGC AGT CAG GTC GAA TCA AT -3'  
Tm = 51.44 °C, MW = 7572  
21.80 OD<sub>260</sub> = 95.01 nmol = 0.72 mg

## Samples Statistically Tested

Q.C. Approved By:

## PLEASE READ BEFORE OPENING TUBES

- \* Store at -20°C. If the oligo is to be used on multiple occasions, resuspend in water or tris-EDTA buffer, divide into smaller aliquots, lyophilize, and store at -20°C.
- \* Contents may appear as either a translucent film or a white powder. This variance does not affect the quality of the oligo.
- \* Please centrifuge tubes prior to opening. Some of the product may have been dislodged during shipping.
- \* Calculations are made using 1 OD<sub>260</sub> = 33 µg / mL

EXHIBIT A

O, AGE 2



## Oligonucleotide Specification Sheet

## Customer Information

Susan Slaugenhaus  
Harvard Institute of Human Genetics  
Massachusetts General Hospital-Boston  
77 Avenue Louis Pasteur HIM Bldg. Rm. 422  
Boston, MA 02115  
6174327025

## Order Information

Order Date : [REDACTED]  
Customer # : 19479  
P.O. # : 0000085288

Sales order # : 148396  
Reference # : 624758

## Oligonucleotide Information

Reference # : 624758  
Purification : Standard Purification  
Sequence Name : sts-T66288-R

Product : DNA Oligo Sample  
Unit Size : 100 nmole  
Bases : 18

Sequence : 5'- AGC TGC AGG GCT ACA TCG -3'

*11x4 = 44  
7x2 = 14  
58*

Molecular Weight :	6,754.00
GC Content :	61.1 %
Tm (50mM NaCl) :	51.11 °C

Amount of Oligo		
15.5	=	75.73
OD <sub>260</sub>	=	nanomoles
	=	mg

Printed 6/9/99

*1590*

## LABELS - PEEL HERE

624758 Integrated DNA Tech  
S. Slaugenhaus 06093  
sts-T66288-R  
5'-AGC TGC AGG GCT ACA TCG -3'  
Tm = 51.11 °C, MW = 6754  
18.50 OD<sub>260</sub> = 75.73 nmol = 0.51 mg

624758 Integrated DNA Tech  
S. Slaugenhaus 06093  
sts-T66288-R  
5'-AGC TGC AGG GCT ACA TCG -3'  
Tm = 51.11 °C, MW = 6754  
18.50 OD<sub>260</sub> = 75.73 nmol = 0.51 mg

## Samples Statistically Tested

## Q.C. Approved By:

## PLEASE READ BEFORE OPENING TUBES

- \* Store at -20°C. If the oligo is to be used on multiple occasions, resuspend in water or tri-(2-hydroxyethyl)amine buffer, divide into smaller aliquots, lyophilize, and store at -20°C.
- Contents may appear as either a translucent film or a white powder. This variance does not affect the quality of the oligo.
- Please centrifuge tubes prior to opening. Some of the product may have been dislodged during shipping.
- Calculations are made using 1 OD<sub>260</sub> = 33 µg / mL

## EXHIBIT B

tigennet\_443

RI507249  
 RI815964  
 RI641051  
 RI687977  
 RI423498  
 RI124938  
 RR694728  
 RR614505  
 RI335811  
 RR777759  
 RI418558  
 RI884728  
 RR283498  
 RI976557  
 RI311822  
 RI377461  
 RI68208  
 R26393  
 Z39668  
 RI364142  
 RI761351  
 R788889  
 RI128688  
 RI248745  
 F82935  
 RR831948  
 H62593  
 RR293845  
 RI12315  
 H64151  
 PT35366  
 RI627686  
 RR663793  
 RI761531  
 FB3591  
 FB9782  
 RR297421  
 RI3841374  
 RR168873  
 RI228881  
 RR329668  
 H21488  
 RI858892  
 RR944782  
 RR958258  
 RR475163  
 RR639746  
 C81592  
 AI015265  
 AR874645  
 K40667  
 RI418967  
 RR763375  
 RI420558  
 RI644662  
 RI480581  
 RI642451  
 RI756265  
 RR798251  
 RR178838  
 2615122  
 RR629475  
 RR997597  
 RV160459  
 RL040169

tigennet\_449

S<=50 50<S<=100 100<S<=150 150<S<=200 S>200

## APPENDIX A

Page 1

SEQ ID NO: 2  
<400> 2  
----- sts-T66288-f  
----- sts-T66288-r

agatcagctg atgccggagg gtttgaaggcc ggcgcgcgag ggagcgagggt cgcaagtggaca 60  
ggggcgccg atcggaccca gyctgccccg ccgtaccccg ctgcgtcccg cgctcccggcc 120  
ccagcatgac agcccgccg ggtccgcgag gctcaagagac ctagcggtt ctgacccccca 180  
accggggta tgggaccccg gggggccctt caccggcccc tccgacaccc ccagaaggagg 240  
aagacattcg ccgtcgatctc aaataactttt tcatgatgtcc ctgcgacaaag tttcgagccaa 300  
aggggccgaa gcctgtcaag ctgtatgctgc aagtggtcaa gatcctggtg gtcaacgggtgc 360  
agtcattcctt gtttgtggctc agtaatcaggc tggctgtgac attccggaa gagaacaccca 420  
tcggccttcg aciaccttcg ctgtctggct actcggacgg agcggtatgac accttcggcag 480  
cctacacgctg ggaaaggcagctg taccaggccca tcttccatgc tgtggccag tacctggcgt 540  
tgcctgacgt gtuaactggcc cggatgtcg atgtccgtgg tgggggtgac ccttggacca 600  
atggctcagg gcttgcgtctc tgccaggcggt actaccacccg aggccacgtg gaccggccca 660  
acgacacatt tgacattgtt ccgatggtg ttactgactg catccagggt gatcccccg 720  
aggggccccc tccggccccc agcgacgatc tcaccctttt gaaaggcgc tccagttaca 780  
agaacctcac gctcaaaattc cacaaggctgg tcaatgtcac catccactc cggctgaagaaga 840  
ccattaacct ccagagcctc atcaataatg agatcccgga ctgctataacc ttcaagcgttcc 900  
tgatcagctt tgacaacaaaa gcacacagtg ggccggatccc catcaggctg gagacccagg 960

cccacatcca ggaggtaag caccaggc tcttccagca cggagacaac agcttccggc 1020  
tcctgttgta cgtgggtc atccctcacct gctccctgtc ctccctc tcgcggcgct 1080  
cactcctcg agycttcctg ctgcagaacg agtttgtgg gttcatgtgg cggcagcggg 1140  
gacgggtcat caygctgtgg gagcggctgg aatttgtcaa tggctggtag atcctgtctcg 1200  
taccaggcga tggctcacc atotcggca cccatcatgaa gatcggcatac gaggccaaaga 1260  
acttggcggag ctacgacgtc tgcaaggatcc tcctggcac ctgcacgctg ctgtgtggg 1320  
tggcggtgat ccgctacatcg acctttttcc acaactacaa tatcctcatc gccacactgc 1380  
gggtggccct gcccaggcgtc atgcgtttct gctgctggcgt ggctgtcatc tacctgggt 1440  
actgcttctg tggctggatc gtgtggggc cctatcatgt gaagttccgc tcactctcca 1500  
tggtgtctga gtgcctgttc tcgctcatca atgggacgaa catgttgtg acgttcggcg 1560  
ccatgcggc gcagcaggc gcagcaggc tggtgtggct ctctcccg ctctacccctt 1620  
actccttcat cagccatcttc atctacatgg tgctcagccct ttcatcgcg ctcatcacccg 1680  
ggcctacga ciaccatcaag catccccggc gcgcaggcgc agaggagac gagctggagg 1740  
ccatcatcg acatggccag gacagccca cctccggcaa gttccgcgc gggaggcgct 1800  
cgccctgcg ctttctgc tgctcgaaa gggacccctc ggaggaggat tcgtgttg 1860  
tgaatgtatt cgacctgact ggcggtggac cgtaggccct ggactgcaga gacccccc 1920  
cccgaccccg cttatatttt tgtaggggtt gtttttaagg atcggtctcc tcgcggcccc 1980  
gaggaggcgc tggaccttcc tggtcgacc ctggggggc gggagactgg gtgggggggg 2040  
tggtaataa ε. 2051

**APPENDIX B**

# The I.M.A.G.E. Consortium

*"Sharing resources to achieve a common goal - the discovery of all genes"*

[Begin new search](#) | [Begin new Clone search](#)

## I.M.A.G.E. Clone Query Results:

Your search returned **2** results! Here they are:


Result Number	CLONE ID	ROW POS	COL POS	PLATE	GB ACCNUM	SEQ LENGTH	GB DATE CREATED	DATE MODIFIED	CDNA LIBR ID	SPECIES	TISSUE TYPE	VECTOR NAME
1	2517653	1	6	6268	AI815981	448	Jul 09 1999 12:00AM	Apr 17 2003 05:06PM	1341	human	brain/CNS	pBluescript SK+
2	2517653	1	6	6268	AI816064	706	Jul 09 1999 12:00AM	Apr 17 2003 05:06PM	1341	human	brain/CNS	pBluescript SK+

[Begin new search](#) | [Begin new Clone search](#)


- [I.M.A.G.E. Consortium home page](#)
- [BBRP home page](#)
- [LLNL Programs, Projects, Centers and Consortia](#)

## APPENDIX C

f1 (+) origin 138-444  
 $\beta$ -galactosidase  $\alpha$ -fragment 463-816  
multiple cloning site 653-760  
lac promoter 817-938  
pUC origin 1158-1825  
ampicillin resistance ( $bl\alpha$ ) ORF 1976-2833



**pBluescript SK (+/-) Multiple Cloning Site Region  
(sequence shown 601-826)**



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**